Tagged with Biotech,

biotech The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million since 2006, and strives to deliver its pipeline of innovative medicines to treat seriously ill patients in Mexico.   You…

biotech The founder of this spin-off of the Autonomous University of the State of Morelos focusing on biologicals for human and veterinary use offers an overview of how the company came into life, the lack of culture at Mexican universities of filing patents for academic research and the potential of the…

innovation Hugo Sigman explains how understanding problems in the same way as opportunities helped his company to become what is today, a successful Argentinian conglomerate where life and science is the backbone of multiple businesses.   Please start by describing the Insud group as it stands today, and where it operates.…

biotech Bioceres manages investments in agricultural biotechnology and related sciences. The company’s CEO, Federico Trucco, discusses the potential of Argentina’s biotech scene to become a world-class drug developer in biopharma as well as Bioceres’ own investments in the sector.   How did you become involved with Bioceres? I have known the…

biotech For many years, Spain’s biotechnology sector was lagging behind the powerhouses of countries like the US and UK. Today, the sector touts a significantly different story, due to strategic investments by Spain’s government. Regina Revilla, president of Spain’s biotech association ASEBIO, details the history of biotech in Spain and outlines…

amgen Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more sustainable health ecosystem for the future of Spain. You became general manager of Amgen Iberia in 2012, in the middle…

amgen Roland Wandeler, general manager of Amgen Iberia, discusses the affiliate’s commitment to innovation, clinical trials, and the importance of providing both medicines and solutions in order to foster a more sustainable health ecosystem for the future of Spain. You became general manager of Amgen Iberia in 2012, in the middle…

Cell2B David Malta and Daniela Couto, Co-founders of Cell2B, discuss the company’s origins and plans to achieve market authorization, and what makes the fledgling company the partner of choice.   What do you see as Portugal’s capacity for the local life sciences industry to grow? DM: Portugal is one of the best-positioned…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…

Botanical drugs The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and US markets. Mr. Hsu, can you please introduce our readers to yourself and to TCM Biotech? Shining Hsu (SH): I…